Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: Towards better tolerability?

Rheumatology

Volumn 46, Issue 6, 2007, Pages 911-919

  Brune, Kay ^a   Furst, D E ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CHLOROQUINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MORPHINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENAZONE DERIVATIVE; PHENYLBUTAZONE; PIROXICAM; PLACEBO; PROPYPHENAZONE; PROQUAZONE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; TENOXICAM; TUBOCURARINE CHLORIDE;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME SPECIFICITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERALGESIA; KIDNEY DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SILENT MYOCARDIAL INFARCTION; STROKE; UVEA DISEASE;

CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; HYPERALGESIA; PROSTAGLANDINS; TISSUE DISTRIBUTION;

EID: 34447343765     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem070     Document Type: Review

References (63)

1. FitzGerald GA, Patrono G. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
2. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
3. Morham SG, Langenbach R, Loftin CD et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:73-82.
4. Langenbach R, Morham SG, Tiano HF et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-92.
5. Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Discov 2003;2:179-91.
6. Brune K, Zeilhofer HU. Antipyretic analgesics: Basic aspects. In: McMahon SB, Koltzenburg M, eds. Textbook of pain, 5th edn. Elsevier, 459-70.
7. Brune K. How aspirin might work: A pharmacokinetic approach. Agents Actions 1974;4:230-2.
8. Brune K, Hinz B. The discovery and development of antiinflammatory drugs. Arthritis Rheum 2004;50:2391-9.
9. Dencker L, Lindquist NG, Ullberg S. Distribution of an 125l-labelled chloroquine analogue in a pregnant macaca monkey. Toxicology 1975;5:255-65.
10. Waser PG, Nickel E. Electromicroscopic and autoradiographic studies of normal and denervated endplates. Prog Brain Res 1969;31:157-69.
11. Brune K, Gubler H, Schweitzer A. Autoradiographic methods for the evaluation of ulcerogenic effects of anti-inflammatory drugs. Pharmacol Ther [B] 1979;5:199-207.
12. Rainsford KD, Schweitzer A, Brune K. Autoradiographic and biochemical observations on the distribution of non-steroid anti-inflammatory drugs. Arch Int Pharmacodyn Ther 1981;250:180-94.
13. Weaver ML, Flood DJ, Kimble EF, Fujimoto RA. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: An effect not seen with other cyclooxygenase-2 inhibitors. Ann Rheum Dis 2003;62(Suppl. 1):378 (Abstract AB0044).
14. Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987;1:89-96.
15. Okuyama S, Aihara H. The mode of action of analgesic drugs in adjuvant arthritic rats as an experimental model of chronic inflammatory pain: possible central analgesic action of acidic nonstaroidal antiinflammatory drugs. Jpn J Pharmacol 1984;35:95-103.
16. Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:80S-4S.
17. Laporte JR, Carne X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on upper gastrointestinal bleeding. Lancet 1991;337:85-9.
18. Henry D, Lim LL, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. Br Med J 1996;312:1563-6.
19. Day RO, McLachlan AJ, Graham GG, Williams KM. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999;36:191-210.
20. Crofford U, Lipsky PE, Brooks P et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000;43:4-13.
21. Verburg KM, Maziasz TJ, Weiner E, Loose L, Geis GS, Isakson PC. Cox-2-specific inhibitors: Definition of a new therapeutic concept. Am J Ther 2001;8:49-64.
22. Brune K, Hinz B. Seledive cyclooxygenase-2 Inhibitors: Similarities and differences. Scand J Rheumatol 2004;33:1-6.
23. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill, 2005.
24. Hinz B, Brune K. Cyclooxygenase-2 - 10 years later. J Pharmacol Exp Ther 2002;300;367-75.
25. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15.
26. Park JY, Pillinger MH, Abramson SB. Prostaglandin E(2) synthesis and secretion: The role of PGE(2) synthases. Clin Immunol 2006;119:229-40.
27. Bombardier C, Laine L, Reicin A et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patents with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
28. Hinz B, Dormann H, Brune K. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treaftnent with diclofenac compared with calecoxib and rofecoxib. Arthritis Rheum 2006;54:282-91.
29. Scott G, Rordorf C, Reynolds C et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004;43:467-78.
30. Samad TA, Moore KA, Sapirstein A et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410:471-5.
31. Reinold H, Ahmedi S, Depner UB et al. Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest 2005;115:673-9.
32. Ahmadi S, Lippross S, Neuhuber WL, Zeilhofer HU. PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 2002;5:34-40.
33. Harvey RJ, Depner UB, Wassle H et al. GlyR alpha3: An essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 2004;304:884-7.
34. Pincus T, Wang X, Chung C, Sokka T, Koch GG. Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: Face validity of self-report questionnaire ratings. J Rheumatol 2005;32:533-9.
35. Smith CJ, Zhang Y, Koboldt CM et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998:95:13313-18.
36. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymos. J Clin Invest 2001;107:1491-5.
37. Buvanendran A, Kroin JS, Berger RA et al. Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology 2006;104:403-10.
38. Brune K. Prostaglandins, inflammation and anti-inflammatory drugs. Eur J Rheumatol Inflamm 1982;5:335-49.
39. Brune K, Rainsford KD, Wagner K, Peskar BA. Inhibition of anti-inflammatory drugs of prostaglandin production in cultured macrophages. Arch Pharmacol 1981;315:269-76.
40. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Ceiecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003;74:130-7.
41. Liauw HL, Ku E, Brandt KD et al. Effects of Voltaren on arachidonic acid metabolism in arthritis patients. Agents Actions Suppl 1985;17:195-9.
42. Elmquist WF, Chan KK, Sawchuk RJ. Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. Pharm Res 1994;11:1689-97.
43. Benson MD, Aldo-Benson M, Brandt KD. Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis. Semin Arthritis Rheum 1985;15(Suppl. 1):65-7.
44. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005;64:1263-7.
45. Kellstein D, Ott D, Jayawardene S, Fricke J Jr. Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of postoperative dental pain. Int J Clin Pract 2004;58:244-50.
46. Scott G, Rordorf C, Milosavljev S, Faber G. Pharmacokinetics and pharmacodynamics of COX189 in patients with knee or hip primary osteoarthritis. Ann Rheum Dis 2002;61 (Suppl. I): 128 (Abstract THU0233).
47. Esser R, Barry C, Du Z et al. Preclinical pharmacology of lumiracoxib: A novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 2005;144:538-50.
48. Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 2004;32:566-71.
49. Okonek S, Reinecke HJ. Acute toxicity of pyrazolones. Am J Med 1983;75:94-8.
50. Graf P, Glatt M, Brune K. Acidic nonsterold anti-inflammatory drugs accumulating in inflamed tissue. Experientia 1975;31:951-3.
51. Lehmann R, Brzosko M, Kopsa P et al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee ostsoarthritis: A 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin 2005;21:517-26.
52. McKenna F, Borenstein D, Wendt H et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-8.
53. Collantes E, Curtis SP, Lee KW et al. Etoricoxib Rheumatoid Arthritis Study Group. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract 2002;3:10.
54. Fricke J, Davis N, Yu V. An evaluation of the efficacy of lumiracoxib 400 mg, celecoxib 400 mg or placebo for treating pain following dental surgery. Reg Anesth Pain Med 2006;30:A-12.
55. Chang DJ, Desjardins PJ, Chen E et al. Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: A randomized, placebo-controlled clinical trial. Clin Ther 2002;24:490-503.
56. Caldwell B, Aldington S, Weatherall M. Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: A systematic review and meta-analysis. J R Soc Med 2006;99:132-40.
57. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet 2006;368:1771-81.
58. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and non-selective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
59. Schnitzer TJ, Burmester GR, Mysler E et al. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 2004;364:665-74.
60. Farkouh ME, Kirshner H, Harrington RA et al. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial. Lancet 2004;364:675-84.
61. Nissen SE. Adverse cardiovascular effects of rofecoxib. N Engl J Med 2006;355:203-4.
62. Sowers JR, White WB, Pitt B et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. 1: Arch Intern Med 2005;165:161-8.
63. Whitehead A, Simmonds M, Mellein B et al. Blood pressure profile of lumiracoxib is similar to placebo in arthritis patients. Osteoarthritis Cartilage 2006;14(Suppl 2):S168-9 (Abstract P309).